455 related articles for article (PubMed ID: 30738371)
21. Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y
Rollini F; Franchi F; Singh K; Cho JR; Bhatti M; DeGroat C; Hu J; Aggarwal N; Alobaidi Z; Thano E; Ferrante E; Zenni M; Bass TA; Angiolillo DJ
Thromb Haemost; 2016 Nov; 116(6):1060-1069. PubMed ID: 27488362
[TBL] [Abstract][Full Text] [Related]
22. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
23. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
24. Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study.
Alexopoulos D; Vogiatzi C; Stavrou K; Vlassopoulou N; Perperis A; Pentara I; Xanthopoulou I
Cardiovasc Diabetol; 2015 May; 14():68. PubMed ID: 26025572
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet drug selection in PCI to vein grafts in patients with acute coronary syndrome and adverse clinical outcomes: Insights from the British Cardiovascular Intervention Society database.
Sirker A; Kwok CS; Kontopantelis E; Johnson T; Freeman P; de Belder MA; Ludman P; Zaman A; Mamas MA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):659-665. PubMed ID: 29356278
[TBL] [Abstract][Full Text] [Related]
26. Periprocedural platelet inhibition with cangrelor in P2Y
Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
[TBL] [Abstract][Full Text] [Related]
28. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
[TBL] [Abstract][Full Text] [Related]
29. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study.
Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ
Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041
[TBL] [Abstract][Full Text] [Related]
30. Ticagrelor or prasugrel versus clopidogrel in patients undergoing percutaneous coronary intervention for chronic coronary syndromes.
Koshy AN; Giustino G; Sartori S; Hooda A; Feng Y; Snyder C; Dasgupta S; Kumar KR; Krishnamoorthy-Melarcode P; Sweeny J; Khera S; Serrao GW; Sharma R; Dangas G; Kini AS; Mehran R; Sharma SK
EuroIntervention; 2023 Mar; 18(15):1244-1253. PubMed ID: 36660810
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Lee YS; Jin CD; Kim MH; Guo LZ; Cho YR; Park K; Park JS; Park TH; Kim YD
Circ J; 2015; 79(6):1248-54. PubMed ID: 25959558
[TBL] [Abstract][Full Text] [Related]
32. Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Tscharre M; Egger F; Machata M; Rohla M; Michael N; Neumayr M; Zweiker R; Hajos J; Adlbrecht C; Suppan M; Helmreich W; Eber B; Huber K; Weiss TW
PLoS One; 2017; 12(6):e0179349. PubMed ID: 28632784
[TBL] [Abstract][Full Text] [Related]
33. Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome. A pharmacodynamic randomised study.
Laine M; Frère C; Toesca R; Berbis J; Barnay P; Pansieri M; Michelet P; Bessereau J; Camilleri E; Ronsin O; Helal O; Paganelli F; Dignat-George F; Bonello L
Thromb Haemost; 2014 Feb; 111(2):273-8. PubMed ID: 24154787
[TBL] [Abstract][Full Text] [Related]
34. A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.
Westman PC; Lipinski MJ; Torguson R; Waksman R
Cardiovasc Revasc Med; 2017 Mar; 18(2):79-85. PubMed ID: 28089137
[TBL] [Abstract][Full Text] [Related]
35. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
36. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y
Chyrchel B; Drożdż A; Długosz D; Stępień EŁ; Surdacki A
Int J Med Sci; 2019; 16(2):264-275. PubMed ID: 30745807
[No Abstract] [Full Text] [Related]
37. Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016.
Dayoub EJ; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Giri J; Groeneveld PW
JAMA Intern Med; 2018 Jul; 178(7):943-950. PubMed ID: 29799992
[TBL] [Abstract][Full Text] [Related]
38. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
[TBL] [Abstract][Full Text] [Related]
39. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
40. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.
Rollini F; Franchi F; Cho JR; DeGroat C; Bhatti M; Muniz-Lozano A; Singh K; Ferrante E; Wilson RE; Dunn EC; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
Eur Heart J; 2016 Sep; 37(35):2722-30. PubMed ID: 26848148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
